

PRECEPTORSHIP PROGRAMME

Metastatic Bladder and Kidney Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

SINGAPORE

4-5 SEPTEMBER 2019

Co-Chairs

Ravindran Kanesvaran, SG
Naveen Vasudev, UK

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Singapore
4-5 September 2019

CO-CHAIRS: Ravindran Kanesvaran, Singapore
Naveen Vasudev, United Kingdom

SPEAKERS: Lui Shiong Lee, Singapore
Quan Sing Ng, Singapore
Nye-Thane Ngo, Singapore
Tanujaa Rajasekaran, Singapore
Chee Keong Toh, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 4 September 2019

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Ravindran Kanesvaran, SG Naveen Vasudev, UK
09:15-10:25 70'	SESSION 1 Pathology and molecular pathology	Chair: Naveen Vasudev, UK
20'	Bladder cancer	Nye-Thane Ngo, SG
20'	Kidney cancer	Nye-Thane Ngo, SG
15'	Clinical applications of molecular pathology	Chee Keong Toh, SG
15'	Discussion	Faculty
10:25-10:55	Coffee break	
10:55-12:30 95'	SESSION 2 How to treat metastatic bladder cancer	Chair: Chee Keong Toh, SG
20'	Chemotherapy	Chee Keong Toh, SG
20'	Immunotherapy	Ravindran Kanesvaran, SG
15'	The role of surgery in metastatic disease	Lui Shiong Lee, SG
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
12:30-13:00	Lunch	
13:00-13:30	Tour of NCCS premises	
13:30-15:20 110'	SESSION 3 How to treat metastatic Renal Cell Cancer (mRCC)	Chair: Ravindran Kanesvaran, SG
15'	Surgery: Is there a role for cytoreductive nephrectomy?	Lui Shiong Lee, SG
20'	Anti-VEGF therapy and mTOR inhibition	Quan Sing Ng, SG
20'	Immunotherapy and combination therapies	Naveen Vasudev, UK
10'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
15:20-15:50	Coffee break	
15:50-17:05 75'	SESSION 4 Debate of the day	Chair: Naveen Vasudev, UK
30'	Should VEGFR TKI + CPI combination be the standard first-line systemic therapy for all mRCC patients? YES/NO	Quan Sing Ng, SG Chee Keong Toh, SG
15'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
19:00	Dinner	

Thursday, 5 September 2019

09:00-10:05 65'	SESSION 5 Personalized therapy in bladder cancer and RCC	Chair: Naveen Vasudev, UK
25'	The search for biomarkers in bladder cancer	Tanujaa Rajasekaran, SG
25'	The search for biomarkers in mRCC	Naveen Vasudev, UK
15'	Discussion	Faculty
10:05-10:35	Coffee break	
10:35-11:50 75'	SESSION 6 Side effects	Chair: Ravindran Kanesvaran, SG
10'	Chemotherapy in bladder cancer	Ravindran Kanesvaran, SG
15'	TKIs and mTOR inhibitors in RCC	Naveen Vasudev, UK
20'	Immunotherapy	Tanujaa Rajasekaran, SG
30'	Participants clinical case discussion (2x15')	Faculty
11:50-12:05 15'	Conclusion and farewell	Ravindran Kanesvaran, SG Naveen Vasudev, UK
12:05-13:05	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion